FINHUB Insights

MCK · Q1 FY26 · Apr 1 – Jun 30, 2025

McKesson Q1 FY26: where the revenue came from and where it went

McKesson Q1 FY26: revenue $97.8B (+23% year over year). Net profit $0.8B. Largest cohort U.S. Pharmaceutical $90B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2025
Reported
Aug 6, 2025 10-Q
Sankey diagram of McKesson's income statement for Q1 FY26: revenue of $97.8 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$97.8B +23% year over year
Gross profit$3.3B 3% margin
Operating profit$1B 1% margin
Net profit$0.8B 1% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Jun 30, 2025).
ItemValueShare of revenueYear over year
Revenue 97.8 100% +23%
U.S. Pharmaceutical 90 92% +34%
International 3.7 4% +8%
Medical-Surgical Solutions 2.7 3% +3%
Prescription Technology 1.4 1% +15%
Cost of revenue−94.597%
Gross profit3.33% margin−1pp
SG&A−2.22%+0pp
Operating profit11% margin+0pp
Tax−0.2
Net profit0.81%+0pp
Filing on EDGAR More quarters of MCK

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters